ARS Pharmaceuticals Inc
SPRY
Company Profile
Business description
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Contact
11682 El Camino Real
Suite 120
San DiegoCA92130
USAT: +1 858 771-9307
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
167
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
Inflation is a key risk to shareholders. Here’s why these two ASX shares benefit from higher inflation.
stocks
Undervalued ASX retailer benefiting from rebound in spending
Uplift in sales momentum continues.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,874.20 | 25.80 | 0.29% |
| CAC 40 | 8,100.90 | 5.26 | -0.06% |
| DAX 40 | 24,097.11 | 20.24 | 0.08% |
| Dow JONES (US) | 48,114.26 | 302.30 | -0.62% |
| FTSE 100 | 9,842.70 | 157.91 | 1.63% |
| HKSE | 25,468.78 | 233.37 | 0.92% |
| NASDAQ | 23,111.46 | 54.05 | 0.23% |
| Nikkei 225 | 49,512.28 | 128.99 | 0.26% |
| NZX 50 Index | 13,295.91 | 129.04 | -0.96% |
| S&P 500 | 6,800.26 | 16.25 | -0.24% |
| S&P/ASX 200 | 8,585.20 | 21.60 | 0.25% |
| SSE Composite Index | 3,870.28 | 45.47 | 1.19% |